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Propositions
1. RNAi-based gene therapy is a promising strategy for treatment of liver diseases 
(this thesis).
2. Despite initial skepticism, it is possible to deliver and express silencing 
constructs in a tissue specific manner (this thesis). 
3. Despite careful design of shRNA and miRNA, unanticipated variants of siRNA 
are produced that may have serious implications for RNAi therapy. One of the 
biggest challenges is further investigation of differential processing and its 
consequences (this thesis).
4. Understanding and overcoming toxicity and off-targeting related problems is 
the major challenge of RNAi based gene therapy (this thesis).
5. Even marginal shRNA doses can already trigger histological detectable 
hepatoxicity, increased hepatocyte apoptosis and global deregulation of 
hepatic miRNA (Beer et al., 2010, Mol Ther; 18: 161-170).
6. Inducible expression of artificial miRNA may be an excellent solution for overcome 
toxicity problems with RNAi however inducible expression system itself may 
induce toxic effects (Reboredo et al.,2010, Hum Gene Ther; 19: 1233-1247).
7. Understanding the role of miRNAs leads to future insights into disease 
pathogenesis, diagnosis and treatment (Ha, Immune Netw, 2011, 11: 135-154).
8. “Despite the enormous num ber of possible miRNA sequences, the small 
amount of change in miRNAs implies that the remaining evolutionary space 
for innova tion is limited; in other words, miRNAs have approached molecular 
perfection” (Kosik, 2013, Nature, doi: 10.1038/nature11956).
9. RNAi has a central role in regulating biological processes: from changing the color 
of flowers through regulation and inhibition of disease related genes expression.
10. The approval of uniQure’s product Glybera in the European Union will 
substantially change the therapeutic landscape. When using the knowledge 
of Glybera, hopefully the approval of AAV-based RNAi gene therapy will 
follow in the near future.
11. Small discoveries brings us step closer to big discoveries.
12. We should be thankful for our talents. 
